Skip to content

omega-3 supplement in attention deficit hyperactivity disorder

The effectiveness of omega-3 supplement as an adjunctive therapy in children with attention deficit hyperactivity disorder

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016060128182N2
Enrollment
66
Registered
2017-01-23
Start date
2016-03-19
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult ADHD (Attention-deficit hyperactivity disorder ). Hyperkinetic disorder, unspecified

Interventions

Intervention 1: One group of patients are randomly assigned to receive methylphenidate in the intervention group. Methylphenidate 10 mg is prescribed for the first week, a daily tablet (half tablet in
in the second week, two tablets are daily prescribed (one in the morning at 8 o'clock, one at 16 o'clock)
if the weight is above 30 pounds, 3 tablets will be daily prescribed in the second week (one and a half tablet each morning at 8 o'clock, one and a half tablet at 16 o'clock). Therapeutic dosage of om
if the weight is above 30 pounds, 3 tablets will be daily prescribed in the second week (one and a half tablet each morning at 8 o'clock, one and a half tablet at 16 o'clock). Therapeutic dosage of pl
Treatment - Drugs
Placebo
One group of patients are randomly assigned to receive methylphenidate in the intervention group. Methylphenidate 10 mg is prescribed for the first week, a daily tablet (half tablet in morning at 8 o'

Sponsors

Kurdistan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 12 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Diagnosis of ADHD based on DSMIV age between 6-12 Exclusion Criteria: receiving of omega3 suplement during past 6 months; presence of seizures; mental retardation; having any psychiatric disorders

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Improvement in Attention-deficit symptoms. Timepoint: Baseline, second, fourth and eighth weeks after intervention. Method of measurement: Conner's and ADHD Rating Scales.;Improvement in Impulsivity symptoms. Timepoint: Baseline, third and sixth weeks after intervention. Method of measurement: Conner's and ADHD Rating Scales–Self-Report.;Improvement in hyperactivity symptome. Timepoint: Baseline, third and sixth weeks after intervention. Method of measurement: Conner's and ADHD Rating Scales–Self-Report.

Secondary

MeasureTime frame
Severity of ADHD symptoms. Timepoint: Baseline, second, fourth and eighth weeks after intervention. Method of measurement: ADHD Rating Scales, CGI.;Side effect. Timepoint: second, fourth and eighth weeks after intervention. Method of measurement: Side effects quesionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSoleiman Mohammadzadeh

Kurdistan University of Medical Sciences

dr.mohammadzadeh86@gmail.com00

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026